Frontotemporal Disorders Treatment Market
Market Insights on Frontotemporal Disorders Treatment covering sales outlook, demand forecast & up-to-date key trends
Frontotemporal Disorders Treatment Market by Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants), by Treatment (Behavioral Symptoms Management, Psychological Symptoms Management) & Region for 2022-2028
Frontotemporal Disorders Treatment Market Overview
[213 Pages Report] The global Frontotemporal Disorders Treatment Market value at around US$ 343.8 Mn in 2022, registering Y-o-Y growth of 4.4%. The market is projected to increase at a CAGR of 4.6% and reach a valuation of US$ 451.4 Mn by 2028.
Frontotemporal Disorders Treatment Market Size (2022) |
US$ 343.8 Mn |
Sales Forecast (2028) |
US$ 451.4 Mn |
Global Market Growth Rate (2022 to 2028) |
4.6% CAGR |
Share of Top 5 Frontotemporal Disorders Treatment System Providers |
50% |
Currently, frontotemporal disorders treatment holds a share of 4.4% of the global neurological disorder treatment market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
How The Market Progressed Till June 2022?
Particulars |
Details |
H1, 2021 |
4.69% |
H1, 2022 Projected |
4.64% |
H1, 2022 Outlook |
4.44% |
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 20 ↓ |
BPS Change – H1, 2022 (O) – H1, 2021 |
(-) 25 ↓ |
As per the FMI analysis, H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 20 BPS. However, In H1-2022, the market growth rate of frontotemporal disorders treatment is expected to fall by 25 basis point share (BPS).
The decline in the BPS values observed was attributed the fact that there exist no current disease-modifying drugs approved by the regulatory bodies for the treatment of frontotemporal disorders. With growing changes in lifestyle, and the growing global burden of disease in ageing population, the market faced a heavy demand over the last few decades. With a large gap in the demand and supply, the market likely observed this decline in the BPS values.
Conversely, with advancements in behavioural therapy approaches, the management of symptomatic concerns regarding frontotemporal disorders will provide insights into the growth of the overall market during the forecast years.
The market is highly influenced by patient pool, treatment adoption rate, target population group demography, and disease prevalence, under the impact of macro and industry factors.
Frontotemporal Disorders Treatment Demand Analysis (2013-2021) Compared to Market Forecasts (2022-2028)
“Growing Prevalence of Dementia Expected to Propel Demand for Frontotemporal Disorders Treatment Drugs”
During the historical period of 2013 to 2021, the frontotemporal disorders treatment market expanded at a CAGR of 4.4%.
Frontotemporal disorders are a bunch of rare disorders that include shrinkage of a particular portion of the brain that controls personality, language, and behavior. The condition arises due to the degeneration of frontotemporal cells, which is called frontotemporal lobar degeneration (FTLD).
The typical age range for the onset of frontotemporal dementia is 40 to 60 years; however, it can start after 60 years of age, and the maximum life expectancy after diagnosis is 8–10 years.
With severe dearth of frontotemporal disorders treatment drugs for the reliable treatment of frontotemporal disorders, treatment continues to underscore the growing significance of disease management. As frontotemporal disorders treatment exclusively includes symptomatic efforts to date, the condition continues to attract research interests worldwide.
Available frontotemporal disorders treatment drugs and other means of frontotemporal disorders treatment do not stop or even decelerate frontotemporal disorders progression, which further remains a key driving force for growing demand for frontotemporal disorders treatment. Expanding incentives for orphan drug development is identified as a prominent factor pushing revenue growth of the frontotemporal disorders treatment industry.
Considering the aforementioned factors, the global frontotemporal disorders treatment market is anticipated to rise at 4.6% CAGR across the 2022 to 2028 time frame.
What are the Prominent Driving Factors for Frontotemporal Disorders Treatment?
“Increasing FTD Drug Development Grants & Funding by Non-Profit Organizations Driving Market Growth”
Non-profit organizations and disease advocacy & private organizations currently are focusing on supporting FTD drug development as the patient base of FTD is expanding. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal disorders treatment drugs.
These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop FTD and other rare neurological disease progressions.
Rising life expectancy rate is another major factor expected to boost the growth of the frontotemporal disorders treatment market due to the high prevalence of neurological disease among the older population. Population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Factors are Restraining Demand for Frontotemporal Disorders Treatment?
“Misdiagnosis and Lack of Awareness Limiting Adoption of Neurological Conditions Treatment”
Frontotemporal disorders are often misdiagnosed as depression, Parkinson’s, Alzheimer’s, or other psychiatric conditions, thereby limiting the scope of adoption of neurological conditions treatment.
Though clinical trials have resulted in many interventions other than medication, consistently high rate of clinical trial failures is a significant factor that is influencing the growth prospects of neurological conditions treatment.
Which is the Dominant Regional Market for Frontotemporal Disorders Treatment?
“Ongoing Clinical Trials for Frontotemporal Lobar Degeneration (FTLD) to Boost Market Expansion in Western Europe”
Western Europe is expected to contribute 30.5% share in the global frontotemporal disorders treatment market in 2022.
While rapidly growing FTD prevalence and expanding ongoing clinical trials platforms are providing a collective push to the frontotemporal disorders treatment market in Western Europe, research estimates rapid emergence owing to increasing sophistication of the healthcare sector and gradually surging awareness about frontotemporal lobar degeneration (FTLD).
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Country-wise Analysis
What Potential Does the U.S. Frontotemporal Disorders Treatment Market Hold?
“Orphan Drug Development Incentives by FDA to Push the Market Forward”
Frontotemporal dementia falls under rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the U.S. Treatment of FTD falls under auspices of the Orphan Drug Act of 1983 as orphan drug indications are those that affect less than 200,000 people in the U.S.
Orphan drug designation to FTD allows the continuation of clinical trial and orphan drug development with commercial incentives, prioritized consultation by FDA on clinical studies, and reduction in regulatory fees.
Presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool is expected to fuel market growth in the U.S.
How is the Market for Frontotemporal Disorders Treatment Faring in China?
“Higher Prevalence of Frontotemporal Disorders in Older Age Group to Fuel Market Expansion”
China, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment systems market.
The market in China is predicted to develop at the quickest rate due to increased disposable income. Moreover, the market growth is related to increasing prevalence of frontotemporal disorders due to the growing elderly population base, as well as the poor immune system.
Category-wise Insights
Which Disease Indication Will Hold Maximum Sway?
“Initiatives by Mental Treatment Centers for Frontotemporal Dementia Patients to Boost Market Growth”
Based on disease indication, frontotemporal dementia (FTD), holding a massive market value share, remains the most common indication among all that continues to capture clinical research interests.
Rapid development of new frontotemporal dementia therapies will push collaborative activities among clinical research entities, educational institutions, academic laboratories, pharma and biotech centers, and the FDA.
Furthermore, frontotemporal dementia therapeutics are anticipated to witness major contributions from pharmaceutical companies – eventually boosting the funding and clinical trial scenario.
Which Distribution Channel is Driving Demand for Frontotemporal Disorders Treatment Products?
“Hospital Pharmacies Most Preferred Due to Easy Availability of Frontotemporal Disorders Treatment Drugs”
Hospital pharmacies are expected to hold the highest market share over the forecast period. Majority of frontotemporal problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
However, there are no specific treatments available to entirely stop the course of frontotemporal disorders. As a result, doctors may prescribe antidepressant medicines to help with anxiety and other symptoms.
Impact of COVID-19 on Market
The frontotemporal disorders treatment market, like many others, was heavily damaged by the COVID-19 pandemic. An increase in infection fear among persons of all ages has resulted from an increasing number of COVID-positive cases that have resulted in mortality and morbidity all across the world.
In addition, limits on travel and movement, social distance conventions, and hospital beds reserved for COVID patients reduced clinical and hospital visits.
However, the emergence of virtual healthcare consultations and remote patient monitoring, as well as an increase in COVID-19 vaccines and lifting of lockdown limitations, will enable the market for frontotemporal disorders treatment devices to quickly recover and grow significantly over the coming years.
Competitive Landscape
In a highly fragmented landscape of the global frontotemporal disorders treatment market, almost 70% of companies offer generics as their key drug offerings. Operated by a large number of prominent international, multinational, and regional players, the market for frontotemporal disorders treatment is recently witnessing a heap of strategic deals, including acquisitions, collaborations, and alliances.
For instance,
- AstraZeneca Plc recently inked an agreement with Luye Pharma Group, Ltd. over the licensing and sales of Seroquel and Seroquel XR across China and the U.K, in addition to a few other international markets. The drug is occasionally used to address a set of behavioral problems associated with FTD.
Frontotemporal Disorders Treatment Industry Report Scope
Attribute |
Details |
Forecast Period |
2022-2028 |
Historical Data Available for |
2013-2021 |
Market Analysis |
Value in US$ Mn |
Key Regions Covered |
|
Key Countries Covered |
|
Key Market Segments Covered |
|
Key Companies Profiled |
|
Pricing |
Available upon Request |
Key Segments of Frontotemporal Disorders Treatment Industry Research
By Drug Class:
- Cognitive Enhancers
- Antipsychotics
- Antidepressants
- CNS Stimulants
- Others
By Treatment:
- Behavioral Symptoms Management
- Psychological Symptoms Management
By Disease Indication:
- Frontotemporal Dementia
- Primary Progressive Aphasia
- Movement Disorders
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region:
- North America Frontotemporal Disorders Treatment Market
- Latin America Frontotemporal Disorders Treatment Market
- Europe Frontotemporal Disorders Treatment Market
- East Asia Frontotemporal Disorders Treatment Market
- South Asia & Pacific Frontotemporal Disorders Treatment Market
- Middle East & Africa (MEA) Frontotemporal Disorders Treatment Market
Frequently Asked Questions
How much is the frontotemporal disorders treatment market expected to be worth in 2022?
As of 2022, the global frontotemporal disorders treatment market is expected to reach US$ 343.8 Mn.
Which are the top 5 countries driving demand for frontotemporal disorders treatment?
France, China, Germany, India, and the U.S. are the top 5 countries driving most demand for frontotemporal disorders treatment.
Which are the leading companies manufacturing frontotemporal disorders treatment products?
Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, and GlaxoSmithKline Plc. are leading companies in this market.
What is the future growth rate of the frontotemporal disorders treatment market for the forecast period?
The frontotemporal disorders treatment market is expected to rise at a CAGR of around 4.6% during the period of 2022-2028.
Which region has the largest market for frontotemporal disorders treatment?
Western Europe accounts for 30.5% share of the global frontotemporal disorders treatment market.
Table of Content
1. Executive Summary 1.1. Market Overview 1.2. Market Analysis 1.3. FMI Analysis and Recommendations 1.4. Wheel of Fortune 2. Market Introduction 2.1. Market Taxonomy 2.2. Market Definition 3. Frontotemporal Disorders Treatment Market Opportunity Analysis 3.1. Macro-Economic Factors 3.2. Opportunity Analysis & Pipeline Assessment 4. Market Background 4.1. Market Dynamics 4.1.1. Drivers 4.1.2. Restraints 4.1.3. Trends 5. Key Inclusions 5.1. Disease Epidemiology 6. North America Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 6.1. Introduction 6.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021 6.2.1. U.S. 6.2.2. Canada 6.3. Market Value (US$ Mn) Forecast By Country, 2022–2028 6.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021 6.4.1. Cognitive Enhancers 6.4.2. Antipsychotics 6.4.3. Antidepressants 6.4.4. CNS Stimulants 6.4.5. Others 6.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028 6.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021 6.6.1. Behavioral Symptom Management 6.6.2. Psychological Symptoms Management 6.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028 6.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021 6.8.1. Frontotemporal Dementia 6.8.2. Primary Progressive Aphasia 6.8.3. Movement Disorders 6.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028 6.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 6.10.1. Hospital Pharmacies 6.10.2. Retail Pharmacy 6.10.3. Drug Stores 6.10.4. Online Pharmacy 6.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028 6.12. Market Attractiveness Analysis 6.12.1. By Country 6.12.2. By Drug Class 6.12.3. By Treatment Type 6.12.4. By Disease Indication 6.12.5. By Distribution Channel 7. Latin America Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 7.1. Introduction 7.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021 7.2.1. Brazil 7.2.2. Mexico 7.2.3. Rest of Latin America 7.3. Market Value (US$ Mn) Forecast By Country, 2022–2028 7.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021 7.4.1. Cognitive Enhancers 7.4.2. Antipsychotics 7.4.3. Antidepressants 7.4.4. CNS Stimulants 7.4.5. Others 7.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028 7.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021 7.6.1. Behavioral Symptom Management 7.6.2. Psychological Symptoms Management 7.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028 7.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021 7.8.1. Frontotemporal Dementia 7.8.2. Primary Progressive Aphasia 7.8.3. Movement Disorders 7.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028 7.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 7.10.1. Hospital Pharmacies 7.10.2. Retail Pharmacy 7.10.3. Drug Stores 7.10.4. Online Pharmacy 7.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028 7.12. Market Attractiveness Analysis 7.12.1. By Country 7.12.2. By Drug Class 7.12.3. By Treatment Type 7.12.4. By Disease Indication 7.12.5. By Distribution Channel 8. Western Europe Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 8.1. Introduction 8.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021 8.2.1. Germany 8.2.2. U.K 8.2.3. France 8.2.4. Italy 8.2.5. Spain 8.2.6. Rest of Western Europe 8.3. Market Value (US$ Mn) Forecast By Country, 2022–2028 8.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021 8.4.1. Cognitive Enhancers 8.4.2. Antipsychotics 8.4.3. Antidepressants 8.4.4. CNS Stimulants 8.4.5. Others 8.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028 8.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021 8.6.1. Behavioral Symptom Management 8.6.2. Psychological Symptoms Management 8.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028 8.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021 8.8.1. Frontotemporal Dementia 8.8.2. Primary Progressive Aphasia 8.8.3. Movement Disorders 8.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028 8.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 8.10.1. Hospital Pharmacies 8.10.2. Retail Pharmacy 8.10.3. Drug Stores 8.10.4. Online Pharmacy 8.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028 8.12. Market Attractiveness Analysis 8.12.1. By Country 8.12.2. By Drug Class 8.12.3. By Treatment Type 8.12.4. By Disease Indication 8.12.5. By Distribution Channel 9. Eastern Europe Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 9.1. Introduction 9.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021 9.2.1. Russia 9.2.2. Poland 9.2.3. Rest of Eastern Europe 9.3. Market Value (US$ Mn) Forecast By Country, 2022–2028 9.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021 9.4.1. Cognitive Enhancers 9.4.2. Antipsychotics 9.4.3. Antidepressants 9.4.4. CNS Stimulants 9.4.5. Others 9.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028 9.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021 9.6.1. Behavioral Symptom Management 9.6.2. Psychological Symptoms Management 9.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028 9.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021 9.8.1. Frontotemporal Dementia 9.8.2. Primary Progressive Aphasia 9.8.3. Movement Disorders 9.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028 9.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 9.10.1. Hospital Pharmacies 9.10.2. Retail Pharmacy 9.10.3. Drug Stores 9.10.4. Online Pharmacy 9.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028 9.12. Market Attractiveness Analysis 9.12.1. By Country 9.12.2. By Drug Class 9.12.3. By Treatment Type 9.12.4. By Disease Indication 9.12.5. By Distribution Channel 10. Asia Pacific Excluding Japan (APEJ) Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 10.1. Introduction 10.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021 10.2.1. India 10.2.2. China 10.2.3. Australia 10.2.4. ASEAN 10.2.5. Rest of APEJ 10.3. Market Value (US$ Mn) Forecast By Country, 2022–2028 10.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021 10.4.1. Cognitive Enhancers 10.4.2. Antipsychotics 10.4.3. Antidepressants 10.4.4. CNS Stimulants 10.4.5. Others 10.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028 10.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021 10.6.1. Behavioral Symptom Management 10.6.2. Psychological Symptoms Management 10.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028 10.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021 10.8.1. Frontotemporal Dementia 10.8.2. Primary Progressive Aphasia 10.8.3. Movement Disorders 10.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028 10.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 10.10.1. Hospital Pharmacies 10.10.2. Retail Pharmacy 10.10.3. Drug Stores 10.10.4. Online Pharmacy 10.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028 10.12. Market Attractiveness Analysis 10.12.1. By Country 10.12.2. By Drug Class 10.12.3. By Treatment Type 10.12.4. By Disease Indication 10.12.5. By Distribution Channel 11. Japan Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 11.1. Introduction 11.2. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021 11.2.1. Cognitive Enhancers 11.2.2. Antipsychotics 11.2.3. Antidepressants 11.2.4. CNS Stimulants 11.2.5. Others 11.3. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028 11.4. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021 11.4.1. Behavioral Symptom Management 11.4.2. Psychological Symptoms Management 11.5. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028 11.6. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021 11.6.1. Frontotemporal Dementia 11.6.2. Primary Progressive Aphasia 11.6.3. Movement Disorders 11.7. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028 11.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 11.8.1. Hospital Pharmacies 11.8.2. Retail Pharmacy 11.8.3. Drug Stores 11.8.4. Online Pharmacy 11.9. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028 11.10. Market Attractiveness Analysis 11.10.1. By Country 11.10.2. By Drug Class 11.10.3. By Treatment Type 11.10.4. By Disease Indication 11.10.5. By Distribution Channel 12. Middle East and Africa Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 12.1. Introduction 12.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021 12.2.1. GCC Countries 12.2.2. South Africa 12.2.3. Rest of MEA 12.3. Market Value (US$ Mn) Forecast By Country, 2022–2028 12.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021 12.4.1. Cognitive Enhancers 12.4.2. Antipsychotics 12.4.3. Antidepressants 12.4.4. CNS Stimulants 12.4.5. Others 12.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028 12.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021 12.6.1. Behavioral Symptom Management 12.6.2. Psychological Symptoms Management 12.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028 12.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021 12.8.1. Frontotemporal Dementia 12.8.2. Primary Progressive Aphasia 12.8.3. Movement Disorders 12.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028 12.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 12.10.1. Hospital Pharmacies 12.10.2. Retail Pharmacy 12.10.3. Drug Stores 12.10.4. Online Pharmacy 12.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028 12.12. Market Attractiveness Analysis 12.12.1. By Country 12.12.2. By Drug Class 12.12.3. By Treatment Type 12.12.4. By Disease Indication 12.12.5. By Distribution Channel 13. Forecast Factors: Relevance and Impact 14. Driver Restraint Impact Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Profitability and Gross Margin Analysis By Competition 16.4. Competitors Deep Dive (Company Overview, Footprint, Strategies, Financials, Key Development) 16.4.1. Pfizer Inc. 16.4.2. Johnson & Johnson 16.4.3. Sanofi S.A. 16.4.4. Eli Lilly and Company 16.4.5. GlaxoSmithKline Plc. 16.4.6. GlaxoSmithKline Plc. 16.4.7. Mylan N.V. 16.4.8. Merck & Company, Inc. 16.4.9. AstraZeneca plc. 16.4.10. Allergan Plc. 17. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 By Region 17.1. Introduction / Key Findings 17.2. Historical Market Value (US$ Mn) Analysis By Region 17.2.1. North America 17.2.2. Western Europe 17.2.3. Eastern Europe 17.2.4. Latin America 17.2.5. Asia Pacific Excluding Japan 17.2.6. Japan 17.2.7. Middle East and Africa 17.3. Market Value (US$ Mn) Forecast By Region 17.4. Market Attractiveness Analysis By Region 18. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Drug Class 18.1. Introduction/Key Finding 18.2. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021 18.2.1. Cognitive Enhancers 18.2.2. Antipsychotics 18.2.3. Antidepressants 18.2.4. CNS Stimulants 18.2.5. Others 18.3. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028 18.4. Market Attractiveness Analysis By Drug Class 19. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Treatment Type 19.1. Introduction/Key Finding 19.2. Historical Market Value (US$ Mn) Analysis By Treatment Type, 2013-2021 19.2.1. Frontotemporal Dementia 19.2.2. Primary Progressive Aphasia 19.2.3. Movement Disorders 19.3. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028 19.4. Market Attractiveness Analysis By Treatment Type 20. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Disease Indication 20.1. Introduction/Key Finding 20.2. Historical Market Value (US$ Mn) Analysis By Disease Indication, 2013-2021 20.2.1. Frontotemporal Dementia 20.2.2. Primary Progressive Aphasia 20.2.3. Movement Disorders 20.3. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028 20.4. Market Attractiveness Analysis By Disease Indication 21. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Distribution Channel 21.1. Introduction/Key Finding 21.2. Historical Market Value (US$ Mn) Analysis By Distribution Channel, 2013-2021 21.2.1. Hospital Pharmacies 21.2.2. Retail Pharmacy 21.2.3. Drug Stores 21.2.4. Online Pharmacy 21.3. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028 21.4. Market Attractiveness Analysis By Distribution Channel 22. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 22.1. Market Value Share Analysis By All Segment 22.2. Y-o-Y Growth Analysis By All Segment 22.3. Absolute $ Opportunity 23. Assumptions and Acronyms Used 24. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: NIH Estimated Funding for Frontotemporal Dementia Table 02: Frontotemporal Disorders Treatment Market Opportunity Pipeline Analysis (2021) Table 03: Frontotemporal Disorders Treatment Market Opportunity Pipeline Analysis (2021) Table 04: Non-Profit Organizations Driving FTD Therapeutics Development Table 05: Non-Profit Organizations Driving FTD Therapeutics Development Table 06: World Population Aged 65 and Over by Sex: 2015, 2030, and 2050 (Numbers in millions) Table 07: Prevalence of Frontotemporal Dementia, By Region Table 08: Prevalence of Frontotemporal Dementia, By Region Table 09: Prevalence of Primary Progressive Aphasia , By Region Table 10: Prevalence of Primary Progressive Aphasia , By Region Table 11: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country Table 12: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class Table 13: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type Table 14: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication Table 15: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel Table 16: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country Table 17: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class Table 18: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type Table 19: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication Table 20: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel Table 21: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country Table 22: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class Table 23: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type Table 24: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication Table 25: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel Table 26: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country Table 27: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class Table 28: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type Table 29: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication Table 30: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel Table 31: APEJ Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country Table 32: APEJ Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class Table 33: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type Table 34: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication Table 35: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel Table 36: Japan Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class Table 37: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type Table 38: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication Table 39: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel Table 40: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country Table 41: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class Table 42: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type Table 43: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication Table 44: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel Table 45: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Region Table 46: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class Table 47: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Treatment Type Table 48: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication Table 49: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Frontotemporal Disorders Treatment Market Split By Drug Class (2022) Figure 2: Global Frontotemporal Disorders Treatment Market Split Treatment Type (2022) Figure 3: Global Frontotemporal Disorders Treatment Market Split By Distribution Channel (2022) Figure 4: Global Frontotemporal Disorders Treatment Market Split By Disease Indication (2022) Figure 5: Global Frontotemporal Disorders Treatment Market Split By Region (2022) Figure 6: Economic Burden of Major Neurological Disease in United States % (2014) Figure 7: Distribution of Industry Sponsored Clinical Programs for Frontotemporal Disorders Drugs, by Phase Figure 8: Global Impact of Dementia Figure 9: Incidence of FTD By Age Figure 10: Prevalence of Frontotemporal Dementia Across the Globe Figure 11: Prevalence of Primary Progressive Aphasia (PPA) Across the Globe Figure 12: North America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 13: North America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 14: U.S. Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 15: U.S. Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 16: Canada Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 17: Canada Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 18: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country Figure 19: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class Figure 20: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type Figure 21: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication Figure 22: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel Figure 23: Latin America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 24: Latin America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 25: Brazil Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 26: Brazil Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 27: Mexico Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 28: Mexico Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 29: Rest of Latin America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 30: Rest of Latin America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 31: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country Figure 32: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class Figure 33: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type Figure 34: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication Figure 35: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel Figure 36: Western Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 37: Western Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 38: Germany Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 39: Germany Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 40: Italy Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 41: Italy Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 42: France Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 43: France Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 44: U.K. Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 45: U.K. Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 46: Spain Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 47: Spain Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 48: Rest of Western Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 49: Rest of Western Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 50: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country Figure 51: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class Figure 52: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type Figure 53: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication Figure 54: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel Figure 55: Eastern Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 56: Eastern Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 57: Russia Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 58: Russia Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 59: Poland Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 60: Poland Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 61: Rest of Eastern Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 62: Rest of Eastern Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 63: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country Figure 64: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class Figure 65: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type Figure 66: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication Figure 67: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel Figure 68: APEJ Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 69: APEJ Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 70: China Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 71: China Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 72: India Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 73: India Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 74: Australia Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 75: Australia Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 76: ASEAN Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 77: ASEAN Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 78: Rest of APEJ Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 79: Rest of APEJ Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 80: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country Figure 81: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class Figure 82: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type Figure 83: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication Figure 84: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel Figure 85: Japan Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 86: Japan Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 87: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication Figure 88: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type Figure 89: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class Figure 90: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel Figure 91: MEA Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 92: MEA Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 93: GCC Countries Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 94: GCC Countries Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 95: South Africa Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 96: South Afric Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 97: Rest of MEA Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021 Figure 98: Rest of MEA Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028 Figure 99: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country Figure 100: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class Figure 101: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type Figure 102: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication Figure 103: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel Figure 104: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Region Figure 105: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class Figure 106: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type Figure 107: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication Figure 108: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel Figure 109: Global Frontotemporal Disorders Treatment Market Historical Market Value and Y-o-Y, 2013-2022 Figure 110: Global Frontotemporal Disorders Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 111: Global Frontotemporal Disorders Treatment Market Absolute $ Opportunity, 2013–2028
Recommendations
Explore Healthcare Insights
View Reports